Who are Hydralazine/Isorsorbide Dinitrate's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Isosorbide Dinitrate + Hydralazine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/hydralazine-isorsorbide-dinitrate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Hydralazine/Isorsorbide Dinitrate — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hydralazine/Isorsorbide Dinitrate (Hydralazine/Isorsorbide Dinitrate) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vasodilator combination. Area: Cardiovascular.

marketed Vasodilator combination Vascular smooth muscle (hydralazine); soluble guanylate cyclase (isosorbide dinitrate) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Hydralazine/Isorsorbide Dinitrate (Hydralazine/Isorsorbide Dinitrate) — Brigham and Women's Hospital. Hydralazine relaxes blood vessel smooth muscle while isosorbide dinitrate provides nitric oxide to dilate vessels, together reducing cardiac afterload and preload to improve heart function.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Hydralazine/Isorsorbide Dinitrate TARGET	Hydralazine/Isorsorbide Dinitrate	Brigham and Women's Hospital	marketed	Vasodilator combination	Vascular smooth muscle (hydralazine); soluble guanylate cyclase (isosorbide dinitrate)
Isosorbide Dinitrate + Hydralazine	Isosorbide Dinitrate + Hydralazine	Corporal Michael J. Crescenz VA Medical Center	marketed	Vasodilator combination	Nitric oxide pathway; vascular smooth muscle

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Vasodilator combination class)

Brigham and Women's Hospital · 1 drug in this class
Corporal Michael J. Crescenz VA Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Hydralazine/Isorsorbide Dinitrate — Competitive Intelligence Brief. https://druglandscape.com/ci/hydralazine-isorsorbide-dinitrate. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing